MNKD
BEARISH
$2.74
Live
MannKind Corporation · NASDAQ
Target $7.39
(+169.7%)
$2.23
52W Range
$6.51
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 15, 2026
Market cap
$846.1M
P/E
137.0
ROE
N/A
Profit margin
1.7%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
MannKind Corporation presents a high-risk profile characterized by a Piotroski F-Score of 4/9, indicating only stable financial health. There is a severe disconnect between the current market price of $2.74 and the growth-based intrinsic value of $0.14, suggesting the stock is trading at a massive premium. While revenue growth is impressive at 45.8%, the company suffers from negative shareholders' equity (P/B of -16.51) and consistent earnings misses. Bearish insider activity and a 0/100 technical trend further undermine the optimistic analyst target prices.
Key Strengths
Strong revenue growth of 45.8% YoY
High gross margins at 74.79%
Strong analyst consensus (Strong Buy) with a high target price of $7.39
Acceptable liquidity with a current ratio of 1.71
Significant improvement in forward P/E (12.04) compared to trailing P/E (137.00)
Key Risks
Negative book value (Price/Book: -16.51) indicating negative equity
Severe overvaluation relative to intrinsic value ($2.74 vs $0.14)
Poor earnings track record with an average surprise of -129.47% over the last 4 quarters
Negative operating margins (-6.87%) despite high revenue growth
Strong bearish technical trend and negative price momentum (1Y Change: -40.8%)
AI Fair Value Estimate
Based on comprehensive analysis
$0.14
-94.9% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
28
Weak
15
65
20
40
0
AI Verdict
Speculative / High Risk
Key drivers: Negative Equity, Intrinsic Value Gap, Revenue Growth, Insider Selling
Confidence
90%
Value
15/100
Ref P/E, PEG, Graham Number
Positives
- Low forward P/E
Watchpoints
- Trailing P/E of 137
- Negative P/B ratio
- Price far exceeds intrinsic value
Future
65/100
Ref Growth rates
Positives
- 45.8% YoY Revenue growth
- Strong analyst price targets
Watchpoints
- Inconsistent earnings delivery
- Negative operating margins
Past
20/100
Ref Historical trends
Positives
- Recent 1-week recovery (+6.6%)
Watchpoints
- 1-year return of -40.8%
- Consistent earnings misses
Health
40/100
Ref Altman Z-Score, Piotroski F-Score
Positives
- Piotroski F-Score of 4 (Stable)
- Current ratio > 1.5
Watchpoints
- Negative shareholders' equity
- Lack of Altman Z-Score data
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$2.74
Analyst Target
$7.39
Upside/Downside
+169.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for MNKD and closest competitors.
Updated 2026-04-14
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
MNKD
MannKind Corporation
Primary
|
-36.3% | -32.0% | -40.8% | -46.3% | -1.1% | +6.6% |
|
AMPH
Amphastar Pharmaceuticals, Inc.
Peer
|
-5.1% | -51.1% | -30.7% | -35.2% | -36.4% | -6.0% |
|
INMD
InMode Ltd.
Peer
|
-67.3% | -61.5% | -4.0% | -11.4% | +3.0% | -1.9% |
|
ABUS
Arbutus Biopharma Corporation
Peer
|
+34.8% | +48.0% | +34.4% | +0.9% | +3.2% | +6.6% |
|
FTRE
Fortrea Holdings Inc.
Peer
|
-68.8% | -68.8% | +45.4% | -12.7% | +4.8% | -0.7% |
MNK
MannKind Corporation
Primary
5Y
-36.3%
3Y
-32.0%
1Y
-40.8%
6M
-46.3%
1M
-1.1%
1W
+6.6%
AMP
Amphastar Pharmaceuticals, Inc.
Peer
5Y
-5.1%
3Y
-51.1%
1Y
-30.7%
6M
-35.2%
1M
-36.4%
1W
-6.0%
INM
InMode Ltd.
Peer
5Y
-67.3%
3Y
-61.5%
1Y
-4.0%
6M
-11.4%
1M
+3.0%
1W
-1.9%
ABU
Arbutus Biopharma Corporation
Peer
5Y
+34.8%
3Y
+48.0%
1Y
+34.4%
6M
+0.9%
1M
+3.2%
1W
+6.6%
FTR
Fortrea Holdings Inc.
Peer
5Y
-68.8%
3Y
-68.8%
1Y
+45.4%
6M
-12.7%
1M
+4.8%
1W
-0.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
137.0
Forward P/E
12.04
PEG Ratio
N/A
P/B Ratio
-16.51
P/S Ratio
2.42
EV/Revenue
3.28
EV/EBITDA
19.44
Market Cap
$846.1M
Profitability
Profit margins and return metrics
Profit Margin
1.68%
Operating Margin
-6.87%
Gross Margin
74.79%
ROE
N/A
ROA
4.91%
Growth
Revenue and earnings growth rates
Revenue Growth
+45.8%
Earnings Growth
N/A
Q/Q Revenue Growth
+45.82%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
1.71
Good
Quick Ratio
1.41
Good
Cash/Share
$0.56
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.1B
Gross Margin
73.5%
Op. Margin
-6.9%
Net Margin
-14.2%
Total Assets
$0.8B
Liabilities
$0.8B
Equity
$-0.1B
Debt/Equity
-16.53x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
125%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-26
$-0.05
-463.6% surprise
2025-11-05
$0.07
+110.0% surprise
2025-08-06
$0.05
-34.8% surprise
Healthcare Sector Comparison
Comparing MNKD against 393 companies in the Healthcare sector
(24 bullish, 129 neutral, 240 bearish)
P/E Ratio
137.0
This Stock
vs
90.61
Sector Avg
+51.2%
(Expensive)
Profit Margin
1.68%
This Stock
vs
-12.47%
Sector Avg
-113.5%
(Weaker)
Revenue Growth
45.8%
This Stock
vs
124.21%
Sector Avg
-63.1%
(Slower)
Current Ratio
1.71
This Stock
vs
4.56
Sector Avg
-62.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
MNKD
MannKind Corporation
|
BEARISH | $846.1M | 137.0 | -% | 1.7% | $2.74 | |
|
AMPH
Amphastar Pharmaceuticals, Inc.
|
BEARISH | $835.41M | 8.96 | 12.9% | 13.6% | $18.18 | Compare |
|
INMD
InMode Ltd.
|
NEUTRAL | $857.24M | 9.46 | 13.5% | 25.3% | $13.53 | Compare |
|
ABUS
Arbutus Biopharma Corporation
|
BEARISH | $872.03M | - | -38.5% | -237.9% | $4.53 | Compare |
|
FTRE
Fortrea Holdings Inc.
|
BEARISH | $877.03M | - | -102.4% | -36.2% | $9.38 | Compare |
MNKD
MannKind Corporation
BEARISH
Mkt Cap
$846M
P/E
137.0
ROE
-%
Price
$2.74
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-10 | CASTAGNA MICHAEL E | Chief Executive Officer | Purchase | 100,000 | $259,000 |
| 2026-02-27 | SHANNON JAMES SAMUEL | Director | Stock Award | 12,000 | $39,240 |
| 2026-02-27 | TROSS STUART A | Officer | Stock Award | 15,290 | $49,998 |
| 2026-02-27 | HOOPER ANTHONY C | Director | Stock Award | 35,000 | $114,450 |
| 2026-02-27 | CASTAGNA MICHAEL E | Chief Executive Officer | Stock Award | 15,290 | $49,998 |
| 2026-02-27 | PRENTISS CHRISTOPHER B. | Chief Financial Officer | Stock Award | 5,000 | $16,350 |
| 2026-01-08 | TROSS STUART A | Officer | Sale | 47,006 | $297,548 |
| 2025-12-24 | CASTAGNA MICHAEL E | Chief Executive Officer | Gift | 44,171 | - |
| 2025-12-17 | CASTAGNA MICHAEL E | Chief Executive Officer | Sale | 65,804 | $395,482 |
| 2025-12-17 | CASTAGNA MICHAEL E | Chief Executive Officer | Option Exercise | 65,804 | $299,408 |
| 2025-12-16 | CASTAGNA MICHAEL E | Chief Executive Officer | Sale | 42,116 | $252,696 |
| 2025-12-16 | CASTAGNA MICHAEL E | Chief Executive Officer | Option Exercise | 42,116 | $191,628 |
| 2025-12-02 | CASTAGNA MICHAEL E | Chief Executive Officer | Sale | 107,920 | $601,114 |
| 2025-12-02 | CASTAGNA MICHAEL E | Chief Executive Officer | Option Exercise | 107,920 | $491,036 |
| 2025-12-02 | THOMSON DAVID B | General Counsel | Sale | 147,780 | $823,135 |
CASTAGNA MICHAEL E
Chief Executive Officer
2026-03-10
100,000 shares
·
$259,000
SHANNON JAMES SAMUEL
Director
2026-02-27
12,000 shares
·
$39,240
TROSS STUART A
Officer
2026-02-27
15,290 shares
·
$49,998
HOOPER ANTHONY C
Director
2026-02-27
35,000 shares
·
$114,450
CASTAGNA MICHAEL E
Chief Executive Officer
2026-02-27
15,290 shares
·
$49,998
PRENTISS CHRISTOPHER B.
Chief Financial Officer
2026-02-27
5,000 shares
·
$16,350
TROSS STUART A
Officer
2026-01-08
47,006 shares
·
$297,548
CASTAGNA MICHAEL E
Chief Executive Officer
2025-12-24
44,171 shares
CASTAGNA MICHAEL E
Chief Executive Officer
2025-12-17
65,804 shares
·
$395,482
CASTAGNA MICHAEL E
Chief Executive Officer
2025-12-17
65,804 shares
·
$299,408
CASTAGNA MICHAEL E
Chief Executive Officer
2025-12-16
42,116 shares
·
$252,696
CASTAGNA MICHAEL E
Chief Executive Officer
2025-12-16
42,116 shares
·
$191,628
CASTAGNA MICHAEL E
Chief Executive Officer
2025-12-02
107,920 shares
·
$601,114
CASTAGNA MICHAEL E
Chief Executive Officer
2025-12-02
107,920 shares
·
$491,036
THOMSON DAVID B
General Counsel
2025-12-02
147,780 shares
·
$823,135
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
STRONG_BUY
9 analysts
Mizuho
2026-04-13
Outperform
Outperform
Wedbush
2026-03-05
Outperform
Outperform
RBC Capital
2026-02-27
Outperform
Sector Perform
Wells Fargo
2026-02-27
Overweight
Overweight
HC Wainwright & Co.
2026-02-27
Buy
Buy
HC Wainwright & Co.
2026-02-25
Buy
Buy
HC Wainwright & Co.
2026-01-26
Buy
Buy
Truist Securities
2025-11-24
Buy
RBC Capital
2025-11-11
Outperform
Outperform
Wells Fargo
2025-11-11
Overweight
Overweight
Past News Coverage
Recent headlines mentioning MNKD from our newsroom.
Newest → oldest
No matching news yet.